Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28310442 | 0.84 | ALDH1A1 (0.42) | PARP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL22158726 | 0.82 | ALDH1A1 (0.41) | PARP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL29496262 | 0.78 | POLB (0.43) | ALDH1A1MEN1KMT2AMAPTPOLB | |
| Formic Acid SCHEMBL29496205 | 0.77 | ALOX15 (0.37) | PARP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3700594 | 0.76 | TSHR (0.39) | PARP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL9220551 | 0.75 | PARP1 (0.41) | PARP1ALDH1A1MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL28200481 | 0.74 | TSHR (0.38) | PARP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30694972 | 0.71 | ERN1 (0.33) | PARP1ALDH1A1MEN1KMT2AMAPT | |
| Quinoline SCHEMBL2201840 | 0.71 | ALDH1A1 (0.74) | PARP1ALDH1A1MEN1KMT2AMAPT | |
| Quinoline SCHEMBL1287895 | 0.71 | ALDH1A1 (0.74) | PARP1ALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038129-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | claimed |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| WO-2025072437-A1 | HETEROARYL COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ALPHINA THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024038129-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | PFIZER INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2023-06-22 | — | — | US | disclosed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018086703-A1 | DIHYDROPYRIDAZINONES SUBSTITUTED WITH PHENYLUREAS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-17 | — | — | WO | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012067965-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | PARP1 737/4885ALDH1A1 2558/4885MEN1 1333/4885 |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | PARP1 1199/4885ALDH1A1 2689/4885MEN1 1139/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | PARP1 831/4885ALDH1A1 637/4885MEN1 2232/4885 |
| US-20230192690-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | CHRM1, CHRM5, CHRM2 | PARP1 3556/4885ALDH1A1 754/4885MEN1 3103/4885 |
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | CHRM1, CHRM5, CHRM2 | PARP1 3556/4885ALDH1A1 754/4885MEN1 3103/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | PARP1 1199/4885ALDH1A1 2689/4885MEN1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.